Beyond Air preannounces $2.3 million revenue, reaffirms 2026 and 2027 guidance

Beyond Air, Inc. said on October 8, 2026 that it expects preliminary, unaudited revenue of approximately $2.3 million for the quarter ended September 30, 2026¹, which the company said represents the highest quarterly revenue reported, and approximately 30% sequential quarterly growth and 27% growth over the same period last year¹. The company attributed the gain to the successful rollout of the Company's enhanced commercial execution strategy for LungFit PH¹.

CEO Robert Goodman said the results reflect continued adoption of LungFit PH and the value hospitals see in our cylinder-free nitric oxide technology¹. He said the second-generation system remains under review by the FDA, and the company expects demand for the LungFit PH platform to increase significantly following FDA approval¹. Goodman added that the company continues to be pleased with the progress it is seeing with the ongoing PMA supplement process, and that adding transport capability would qualify Beyond Air as a single source nitric oxide provider, which is the current standard across most U.S. hospital systems¹.

On guidance, the company reaffirmed its previously issued revenue guidance of $8 million for calendar year 2026, which excludes revenue from the second-generation LungFit PH system¹, and reaffirmed its revenue guidance of $16 million to $18 million for calendar year 2027, which includes anticipated revenue from the second-generation system, pending FDA approval¹.

The company cautioned that the figure is unaudited, is based on management's preliminary estimates and information available to the Company as of the date of this press release, and remains subject to the completion of the Company's financial closing procedures and the review of its interim financial statements by its independent registered public accounting firm, which has not audited, reviewed or performed any procedures with respect to the preliminary figure¹. Beyond Air said it will report its complete financial results for the quarter ended September 30, 2026 in November 2026¹.